AR126001A1 - Anticuerpos y composiciones anti-nkg2a - Google Patents

Anticuerpos y composiciones anti-nkg2a

Info

Publication number
AR126001A1
AR126001A1 ARP220101426A ARP220101426A AR126001A1 AR 126001 A1 AR126001 A1 AR 126001A1 AR P220101426 A ARP220101426 A AR P220101426A AR P220101426 A ARP220101426 A AR P220101426A AR 126001 A1 AR126001 A1 AR 126001A1
Authority
AR
Argentina
Prior art keywords
seq
nos
amino acid
acid sequences
nkg2a
Prior art date
Application number
ARP220101426A
Other languages
English (en)
Spanish (es)
Inventor
Randi Westh Hansen
Franziska Katharina Uhlenbrock
Nikolaj Dietrich
Anne Worsaae
Michael Monrad Grandal
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of AR126001A1 publication Critical patent/AR126001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP220101426A 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a AR126001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01

Publications (1)

Publication Number Publication Date
AR126001A1 true AR126001A1 (es) 2023-08-30

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101426A AR126001A1 (es) 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a

Country Status (17)

Country Link
US (2) US12012450B2 (cg-RX-API-DMAC7.html)
EP (1) EP4347651A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520577A (cg-RX-API-DMAC7.html)
KR (1) KR20240016991A (cg-RX-API-DMAC7.html)
CN (1) CN117460748A (cg-RX-API-DMAC7.html)
AR (1) AR126001A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022286617A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024772A2 (cg-RX-API-DMAC7.html)
CA (1) CA3222040A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003562A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015982A2 (cg-RX-API-DMAC7.html)
IL (1) IL308695A (cg-RX-API-DMAC7.html)
MX (1) MX2023014320A (cg-RX-API-DMAC7.html)
PE (1) PE20240372A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023553123A1 (cg-RX-API-DMAC7.html)
TW (1) TW202313683A (cg-RX-API-DMAC7.html)
WO (1) WO2022253805A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4644422A1 (en) * 2022-12-28 2025-11-05 BioRay Pharmaceutical Co., Ltd. Anti-nkg2a antibody and use thereof
CN121358774A (zh) * 2023-06-21 2026-01-16 科望(苏州)生物医药科技有限公司 与nkg2a结合的抗体或抗原结合片段及其用途
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
ATE537190T1 (de) * 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
AU2015316993B2 (en) * 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3209687A1 (en) * 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN116693685A (zh) * 2016-04-12 2023-09-05 法国施维雅药厂 抗tim-3抗体及组合物
EP3878869A4 (en) 2018-11-07 2023-04-19 Shanghai Hyamab Biotech Co., Ltd. NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.

Also Published As

Publication number Publication date
US12012450B2 (en) 2024-06-18
JP2024520577A (ja) 2024-05-24
CA3222040A1 (en) 2022-12-08
PH12023553123A1 (en) 2024-03-04
IL308695A (en) 2024-01-01
CN117460748A (zh) 2024-01-26
MX2023014320A (es) 2023-12-13
US20240294638A1 (en) 2024-09-05
EP4347651A1 (en) 2024-04-10
KR20240016991A (ko) 2024-02-06
CL2023003562A1 (es) 2024-07-12
BR112023024772A2 (pt) 2024-02-15
AU2022286617A1 (en) 2023-12-21
WO2022253805A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US20220389100A1 (en) 2022-12-08
PE20240372A1 (es) 2024-03-05
CO2023015982A2 (es) 2024-01-15

Similar Documents

Publication Publication Date Title
PE20231851A1 (es) Proteinas que se unen a nkg2d, cd16 y clec12a
PE20220708A1 (es) Anticuerpos anti-cd73
MX2024002152A (es) Anticuerpos anti-ccr8 y usos de estos.
PE20240363A1 (es) Anticuerpos anti-ccr8 y usos de los mismos
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
PE20090046A1 (es) Anticuerpo recombinante humanizado anti-interleuquina 10
ES2572177T3 (es) Anticuerpos neutralizantes anti-B7RP1 humanos
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
PE20190737A1 (es) Anticuerpos anti-cd27
PE20110797A1 (es) Anticuerpos anti mn
PE20050712A1 (es) Anticuerpos rg1
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
PE20221263A1 (es) Agentes de union a ilt3 y metodos de uso de los mismos
AR110755A1 (es) Anticuerpos dirigidos a hueso
MX2020010653A (es) Anticuerpo anti-muerte programada-ligando 1 y su uso.
MX2024015072A (es) Anticuerpos anti-egfr/met y usos de los mismos
MX2024001067A (es) Composicion farmaceutica y uso.
CO2025004790A2 (es) Anticuerpo anti-il-1r3 humanizado y métodos de uso
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos
PE20230306A1 (es) Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
MX2024015303A (es) Composicion farmaceutica y uso de la misma
PE20230075A1 (es) Anticuerpos anti-flt3 y composiciones
PE20230374A1 (es) Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso